ADM, Vland Form JV For Probiotics In China

by Shivani Kumaresan, Benzinga Staff Writer

October 18, 2021 10:13 AM | 1 min read |

Archer-Daniels-Midland Co ADM and Qingdao Vland Biotech Group Co Ltd (Vland) have formed a joint venture to serve the growing Chinese demand for human probiotics. The financial terms of the arrangement were not disclosed.
The 50-50 joint venture will manufacture and sell human probiotics, bringing together the companies' technology, production, and commercial capabilities.
The parties expect the joint venture to launch in the first half of 2022.
Vland and ADM aim to capture China's retail demand for probiotics, estimated to be $1 billion in 2022, with more than 9% annual growth.
Price Action: ADM shares are trading lower by 0.18% at $63.83 on the last check Monday.

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.